KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Retained Earnings: 2009-2024

Historic Retained Earnings for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to -$1.4 billion.

  • Rigel Pharmaceuticals' Retained Earnings rose 8.07% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 8.07%. This contributed to the annual value of -$1.4 billion for FY2024, which is 1.24% up from last year.
  • As of FY2024, Rigel Pharmaceuticals' Retained Earnings stood at -$1.4 billion, which was up 1.24% from -$1.4 billion recorded in FY2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Retained Earnings peaked at -$1.3 billion during FY2020, and registered a low of -$1.4 billion during FY2023.
  • Moreover, its 3-year median value for Retained Earnings was -$1.4 billion (2024), whereas its average is -$1.4 billion.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Retained Earnings fell by 4.42% in 2022, and later increased by 1.24% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Retained Earnings (Yearly) stood at -$1.3 billion in 2020, then fell by 1.37% to -$1.3 billion in 2021, then declined by 4.42% to -$1.4 billion in 2022, then declined by 1.81% to -$1.4 billion in 2023, then grew by 1.24% to -$1.4 billion in 2024.